Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

HDAC_I inhibits BAP1. 2 / 2

| 2

➶

reach

"Histone deacetylase (HDAC) inhibitors, such as the readily available valproic acid, can reverse this effect of BAP1 loss and may play a role in treated patients with high-risk class 2 uveal melanomas in an adjuvant setting prior to the emergence of overt metastatic disease [XREF_BIBR]."

24713608

➶

reach

"Histone deacetylase (HDAC) inhibitors have been shown to reverse the phenotypic effects of BAP1 loss by inducing morphologic differentiation and transition from a high-risk to a low-risk gene expression profile in uveal melanoma cells."

29497459

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...